Ascletis Pharma, Inc.HKEX: 1672

Next Day Disclosure Return

Oct 16, 2026 at 5:49 AM EDT · Issued by Ascletis Pharma, Inc. via HKEXnews

Filed with HKEX · Stock code 1672 · Oct 16, 2026 at 5:49 AM EDT · 7 pages · English

On 6ix: 6ix.com/news/next-day-disclosure-return-1197

Ascletis Pharma, Inc. on 6ix

Earlier from Ascletis Pharma

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026Oct 6
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026Oct 2
Interim Report 2026Sep 29
Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque PsoriasisSep 29

Later from Ascletis Pharma

Voluntary announcement - ascletis announces positive preclinical data for the most comprehensive once-weekly oral peptide pipeline for the treatment of obesityOct 20

All Ascletis Pharma news releases

Follow Ascletis Pharma into a list and get an email when it puts out news.

Follow Ascletis Pharma